HYPOTHESIS~Given the favourable activity of fluoropyrimidines (5Fluorouracil) which inhibit thymidylate synthase (TS) in nasopharyngeal carcinoma, the investigators hypothesized that TAS-102 may demonstrate efficacy in NPC through targeting TS as well as an additional mechanism of incorporating trifluridine triphosphate into DNA.~OBJECTIVES OF TRIAL~To determine the clinical efficacy of TAS-102 in recurrent and metastatic NPC~To assess the safety and tolerability of TAS-102 in the study population of R/M NPC~To study the pharmacokinetics of TAS-102 in the study population of R/M NPC~To study potential predictive biomarkers for clinical benefit from TAS-102
This is a single-arm, non-randomised study including patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease not amenable to curative treatment, who have received at least 1 regimen of platinum containing chemotherapy.